Combination of first-in-class NBTXR3, radiotherapy, and anti-PD-1 immunotherapy demonstrate efficacy in treating resistant pre-clinical in vivo models of lung cancer

David Linetsky
Point-of-Care Marketing

Brenda Snow
Authentic Patient Voice

Matthew Durham
Omnidynamic Marketing

Paul Theisen
Patient Acquisition

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy

Stacey Gandler
Brand Nourishment

Amy Giles
Increasing Engagement

Suma Ramadas, PhD
Medical Affairs

Bud Bilanich
Success Coach

Daniel Sontupe
Market Access

Frank Burrell
Scientific Storytelling

Joey Cohen
Medication Adherence